Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Theralase Updated Website!!!!
View:
Comment by Pandora on Oct 17, 2020 11:51am
Just what's on those two pages should be worth more than 14 cents yet here we are! Priced on management not content??
Comment by goldn1 on Oct 17, 2020 12:00pm
pandora, one would think tlt wouldn't b hidin this information so everyone has to dif thru their website to find it. How are they so clueless as to get information out. They take the time and expense to extend warrants, gift themselves 16 million options... they could simply issue an update as we need a new influx of investors, the larger the better imo
Comment by Eoganacht on Oct 17, 2020 2:09pm
Thanks for that Jaro1977. Theralase did a nice job on the update. This visual says it all! NMIBC STUDY DRUG TLD-1433 TLD-1433 Mechanism of Action
Comment by Longholder99 on Oct 17, 2020 4:12pm
May explain the big volume day last week. Big stuff on the horizon
Comment by Hempdoc on Oct 17, 2020 6:02pm
  The beauty of our PDT is that it not only causes efficient cancer cell death primarily by apoptosis (a pathway which leads to less localized inflammatory side efffects/toxicity), it neatly generates damage-associated molecular patterns (DAMP), which elicits a favorable anti-tumor immune response.   Dendritic cells (DCs) are our immune system's sentinels that can be pulsed ...more  
Comment by Eoganacht on Oct 17, 2020 6:45pm
Dr. McFarland published a good article in 2018 on the details of immunogenic cell death during apoptotic cancer cell death. Like you write, there is ample evidence that pdt with TLD1433 induces ICD.  Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
Comment by stocksnbonds458 on Oct 17, 2020 8:00pm
Its actually quite exciting for me every time I read about the potential, particularly since we all know they have already cured cancer in patients #5 and #6 in phase 1. They are nearly 2 years cancer free, so we know this treatment truly works. Makes me wanna but more, but i have enough shares now. Having already (truly) cured people of cancer has somewhat de-risked TLT lol
Comment by StevenBirch on Oct 17, 2020 8:37pm
I like the change in tone today, much more positive. The Astros came back from a 3-0 deficit and the Dodgers from 3-1 to force games 7s. TLT has a lot of talent and they don't cheat so it's time to turn this thing around.
Comment by enriquesuave on Oct 17, 2020 9:42pm
Awesome updated pipeline page. I like the “ RUTHERRIN ® (ENHANCED RADIATION THERAPY PLATFORM TECHNOLOGY OR TECHNOLOGY FOR INNOVATION IN RADIATION ONCOLOGY”. This is IMO a potential game changer for radiation oncology. Will allow for simple and cheap to perform clinical trials. No other hardware needed, simply inject Rutherin IV and after a few hours subject organ to low level radiation or ...more  
Comment by Hempdoc on Oct 18, 2020 12:02am
Yes Enrique...I believe that is where we are headed.  A recent feasibility study (completed this past year) of using navigational bronchoscopy to perform PDT w/Photofrin in unresectable peripheral lung cancer demonstrated a significant number/type of adverse events.  Not only did participants have to wait "2 days" after IV Photofrin injection before PDT treatment, they had to ...more  
Comment by Longholder99 on Oct 18, 2020 11:54am
A lot of these developments have been in pipeline and part of the plan from the beginning. The fact that some of it is starting to work out explains the sudden appearance of certain handles with leading questions trying to find anything negative to cling to in order to cast doubt for the masses on behalf of their Bossaccords......or Cannabosses??? Not sure how to frame that one.
Comment by goldn1 on Oct 18, 2020 12:48pm
longh, what has worked out so far? A website update?
Comment by 2b7f6fab on Oct 18, 2020 4:13pm
Thanks for the links.  This updated webpage looks like it was professionally done.  Looks like a big pharma webpage.  Maybe were on a roll now.. And thanks for the warrant extension, appreciated!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250